Objectives: To survey antibiotic resistance among Streptococcus pyogenes isolates collected from 2005 to 2012, to characterize those showing erythromycin resistance and to analyse the association of certain emm types with erythromycin resistance or susceptibility.
Introduction
Streptococcus pyogenes colonizes human mucosal and skin epithelium. This pathogen causes not only bacterial pharyngitis but also a wide variety of mild to severe and life-threatening infections, making it a significant public health problem. 1 The treatment of choice is penicillin, to which S. pyogenes remains universally susceptible. In the most severe cases of S. pyogenes infection, such as necrotizing fasciitis or toxic shock syndrome, the addition of clindamycin is recommended as it halts exotoxin production. In patients allergic to b-lactams, the treatment of choice consists of erythromycin or other macrolides.
High erythromycin resistance rates among S. pyogenes have been a worrisome problem worldwide, causing special alarm in southern European countries 2 -5 during the late 1990s and more recently in Japan. 6 In some regions of Spain, the erythromycin resistance rate exceeded 30% by the mid-1990s 5 and by 1999 a multicentre study reported an average prevalence of resistance of 20%. 7 A similar situation has been observed in the neighbouring countries France and Portugal 3, 8 as well as in other European countries. 9, 10 In the USA, despite some geographical variations, macrolide resistance rates among group A streptococci have remained relatively low (,5%) since the 1990s. 11, 12 Our study group has actively surveyed macrolide resistance among S. pyogenes isolates since 1984. 5 Through 1999 -2005, we found that 21% of S. pyogenes isolates showed erythromycin resistance, with the predominance of the M phenotype of resistance, which confers resistance to 14-and 15-membered macrolides. Nevertheless, in 2004 and 2005, a worrisome increase of isolates with resistance to macrolides, lincosamides and streptogramin B (MLS B phenotype) was documented, 4 when 50% of erythromycin-resistant isolates showed this MLS B phenotype.
The aims of this study were to characterize phenotypically and genotypically all isolates showing erythromycin resistance collected from 2005 to 2012 in Gipuzkoa, northern Spain, to determine the prevalence of resistance to other antimicrobials, to describe the distribution and dynamics of resistant clones and to analyse the association of certain emm types with erythromycin resistance.
Materials and methods

Study area and bacterial isolates
This study was conducted at the Donostia University Hospital, which is the referral hospital for Gipuzkoa (a region of northern Spain) that attends a population of 406000 inhabitants including patients of all ages. All nonduplicated S. pyogenes clinical isolates recovered from all sources of infection (pharynx, ear, skin, genitals and blood and other sterile sites) obtained in the Microbiology Department between January 2005 and December 2012 were included in the study and were tested for antimicrobial susceptibility (n¼12346).
S. pyogenes were identified based on colony morphology, b-haemolysis on blood agar plates and agglutination with specific antisera (Slidex Streptokit; bioMérieux, Marcy-l'Étoile, France) and/or matrix-assisted laser desorption/ionization -time of flight mass spectrometry analysis (MALDI Biotyper 3.0; Bruker Daltonics Inc., Billerica, MA, USA).
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by disc diffusion method. The double-disc assay (D-zone) was used to detect clindamycin-inducible resistance by placing a 2 mg of clindamycin disc 12 mm apart from a 15 mg of erythromycin disc on blood agar plates. 13 For erythromycin-, clindamycin-, tetracycline-and ciprofloxacin-resistant isolates, MICs were determined by the broth microdilution method using Sensititre Microtiter Trays (Trek Diagnostics Systems, East Sussex, UK) and cation-adjusted Mueller -Hinton II broth (bioMè rieux) supplemented with 3%-5% v/v lysed horse blood. Interpretation was performed according to CLSI recommendations. 13 In bacitracin-resistant isolates, the MIC was determined as previously described.
14 As the CLSI has not described an interpretive standard for ciprofloxacin or bacitracin, we defined a low level of resistance to ciprofloxacin when the MIC was 2 -8 mg/L and a high level of resistance when the MIC was ≥16 mg/L. Non-susceptibility to bacitracin was considered when an MIC ≥16 mg/L was detected. Streptococcus pneumoniae ATCC 49619 was used as a control. Multidrug resistance was defined as resistance to three or more antibiotics.
Since 2010, a norfloxacin disc (10 mg) was used to screen for low-level fluoroquinolone resistance. No inhibition zone (,7 mm) around the norfloxacin disc was indicative of fluoroquinolone resistance.
Isolate characterization
emm typing was performed in all macrolide-resistant isolates available for molecular characterization (816/868) and in a random selection of 10% of total isolates (n ¼1251) to analyse the association of specific emm types with erythromycin resistance or susceptibility, according to guidelines provided by the CDC (www.cdc.gov/ncidod/biotech/strep/M-ProteinGene_ typing.htm). Multilocus sequence typing (MLST) (www.mlst.net) was performed for representative emm types. When ,10 isolates had the same emm type and mechanism of resistance, all isolates were typed; otherwise, ≥10% were subjected to MLST. Isolates with the same emm type and sequence type (ST) were considered to belong to the same clone.
Detection of resistance determinants and mutations
Detection of the macrolide resistance genes erm(B), erm(A)TR [formerly erm(TR)] and mef(A) and the tetracycline resistance genes tet(M) and tet(O) was performed by PCR amplification as previously described. 4 Mutations in ribosomal proteins L4 and L22 and in 23S were studied in isolates that showed resistance to erythromycin but were negative for the erm(B), erm(A)TR or mef(A) genes following previously described procedures. 15, 16 The parC and gyrA genes of isolates showing a high level of resistance to fluoroquinolones (ciprofloxacin and levofloxacin MIC ≥16 mg/L) were sequenced as described by Yan et al. 17 Sequences were compared with that of a wild-type strain using the National Center for Biotechnology Information tBLASTx program (GenBank accession numbers AF220946 for the parC gene and AF220945 for the gyrA gene). 
Macrolide consumption
Statistical analysis
Antibiotic resistance rate trends over time were analysed by the x 2 test for trends. The associations of each emm type with macrolide resistance or susceptibility were calculated by Fisher's exact probability test and relative risk (RR). A logistic regression analysis including age (quantitative variable) and the origin of the sample (qualitative variable) was performed (SPSS v20.0).
Results
The susceptibility of 12 346 S. pyogenes isolates was studied. A total of 82.1% (n ¼10 134) were obtained from patients with pharyngeal infections and 0.9% (n ¼ 106) from invasive infections (blood or other sterile sites), 81 of them from bacteraemic patients. Other infection types are shown in Table 1 . Patient age was known in 12 162 patients; 80.5% were paediatric patients (,15 years old) and 19.5% adults. All 12 346 tested isolates were fully susceptible to penicillin (MIC 90 ,0.03 mg/L). 
Erythromycin resistance
Erythromycin-resistant isolate characterization
Of the 868 erythromycin-resistant isolates, 816 (94%) were available for molecular characterization. MLST was performed in 177 isolates representing all emm types detected in the study; among these, 21 different clones were detected (Table 2) . Four clones accounted for 89.2% of resistant isolates: emm12/ST36 (41.1%), expressing the M phenotype; emm11/ST403/ST20/ST21 (21.3%), expressing the MLS B phenotype; emm28/ST52 (14.2%), expressing the MLS B phenotype; and emm4/ST39 (12.6%), expressing the M phenotype. Dividing the study into two periods of 4 years each, all clones were less prevalent during the second period than in the first. Genitals: male glans or urethra (n¼23) and vagina (n¼431). c Others: respiratory samples (n¼59), urinary tract (n¼42), conjunctiva (n¼24), adenopathies (n¼6) and cornea (n¼1). Total  139  195  132  139  95  45  43  28  816  458  312  18  13  7  6  2 a Mutation A2058G in domain V of the 23S gene.
Erythromycin-resistant S. pyogenes clones in northern Spain
Clone emm12/ST36 showed an incidence peak in 2008 followed by a gradual decline. The decreasing trend of the other three main clones began sooner (Table 2) .
emm11 isolates characterized as ST403, ST20 and ST21 were reported as a single clone (emm11/ST403/ST20/ST21) as they differed only in the yqil allele. This emm11 clone showed a decreasing trend, declining from 75 isolates (53.9% of erythromycin-resistant isolates) in 2005 to 2 and 4 isolates in 2011 and 2012, respectively (x 2 test for trend P, 0.001). The emm28/ ST52 clone also decreased over time (x 2 test for trend P ¼ 0.02). The only year showing a higher prevalence of erythromycin resistance in children than in adults (12.2% versus 10.9%) was 2006, although this difference was not statistically significant. This finding was due to the dissemination of a specific clone (emm4/ST39) that almost exclusively affected the paediatric population.
In most (19/21, 90%) erythromycin-resistant clones, the emm type was associated with a single ST. Only emm75 isolates belonged to two STs (ST49 and ST150) of a different group.
Macrolide resistance determinants
The macrolide resistance gene content detected in each clone is shown in Table 2 . A single mef(A), erm(B) or erm(A)TR gene was detected in 96.6% of isolates and 3.2% of isolates harboured more than one resistance gene. In two emm75/ST150 isolates, no resistance genes [erm(B), erm(A)TR or mef(A)], or mutations (in L22, L4 or in domain II of 23S rRNA) were found. In both strains, a mutation consisting of a substitution of an adenine by a guanine in position 2058nt of domain V of the 23S gene (A2058G) (Escherichia coli numbering) was found compared with the S. pyogenes strain ATCC 700294 and with two erythromycin-susceptible emm75 S. pyogenes strains of our collection. The two strains harbouring this unusual mutation and expressing the MLS B phenotype were isolated from a 20-month-old child with exanthema and a 4-year-old child with pharyngitis. There was no apparent linkage between them.
Prevalence of erythromycin resistance among the main emm types
From the total sample (resistant and susceptible isolates), a random selection of 1251 isolates were emm typed to analyse the association of specific emm types with erythromycin resistance. Twenty-nine emm types were detected. Only 11 of these emm types contained erythromycin-resistant isolates, but none was exclusively associated with erythromycin resistance (Table 3) . Nevertheless, emm11, emm12 and emm28 were significantly associated with resistance (P,0.001). In contrast, isolates characterized as emm1, emm2, emm3, emm75, emm77, emm87 and emm89 were significantly associated with erythromycin susceptibility (Table 3) .
Macrolide consumption
Macrolide consumption was similar from 2004 to 2011, with a slight downward trend in clarithromycin consumption, which was compensated by an equivalent increase in azithromycin Coresistance to erythromycin and ciprofloxacin was detected in 0.3% of all isolates (4.3% of erythromycin-resistant isolates). Among erythromycin-and ciprofloxacin-resistant isolates (n ¼ 37), four clones were detected: emm6/ST382 (n ¼ 24, 64.9%), emm11/ST403/ST20/ST21 (n ¼ 8, 21.6%), emm4/ST39 (n¼ 3, 8.1%) and emm48/ST161 (n¼ 2, 5.4%).
Tetracycline resistance was observed in 3.5% of isolates (annual range 7.8% -1.2%). Coresistance to erythromycin and tetracycline was found in 1.7% of all isolates [24% (208/868) of erythromycin-resistant isolates]. Among erythromycin-and tetracycline-resistant isolates (n¼ 208), 18 different clones were identified, the most predominant being emm11/ST403/ST20/ ST21 (n ¼ 166, 79.8%) and emm28/ST52 (n ¼ 7, 3.4%), both of which harboured the tet(M) gene.
An annual range of resistance to bacitracin of 2.2% -0% was observed. No bacitracin-resistant isolates were detected from 2010 onward. All bacitracin-resistant isolates were characterized as emm28/ST52 and expressed the MLS B phenotype. As all bacitracin-resistant isolates were emm typed, it could be deduced that the emm28/ST52 bacitracin-resistant subclone was more prevalent among isolates from perianal and vaginal sites (24/ 600) than in any other location, where it represented ,1% of isolates (74/11 746) (P,0.001, RR 5.21, 95% CI 3.65-7.44).
Antimicrobial resistance rate by patient age and source of infection
By patient age, the prevalence of resistance to erythromycin (9.2% versus 6.6%), clindamycin (5.4% versus 2.3%) and tetracycline (7.5% versus 2.6%) was always significantly higher in adults than in children (P, 0.001). The main erythromycin-resistant clones found by patient age are shown in Table 4 . The annual evolution of erythromycin, clindamycin, tetracycline and bacitracin resistance among children and adults is shown in Figure 2 .
The percentage of resistance by origin of isolates is shown in Table 1 . In a bivariate analysis, pharyngeal isolates showed less erythromycin resistance than skin isolates (P ¼ 0.007), but more resistance than ear isolates (P,0.001). Invasive isolates showed a non-significant lower erythromycin resistance rate (4.7%) than non-invasive isolates (7.1%) (P ¼ 0.45). Isolates from skin infections showed more resistance to tetracycline and bacitracin than pharyngeal isolates. Because skin infections occurred mostly In parentheses, number of isolates available for molecular characterization.
Erythromycin-resistant S. pyogenes clones in northern Spain in adults and otitis occurred mostly in children ,5 years old, a logistic regression analysis was performed, showing that both patient age and the origin of isolates influenced the resistance.
Isolates from older people showed greater resistance independent of the anatomical location of the infection (each year of additional age increased the odds by 1.005, 95% CI 1 -1.01). Nevertheless, only isolates from ear infections were clearly associated (P,0.001) with lower erythromycin resistance independent of the patient age. Skin isolates could not be associated with erythromycin resistance independent of patient age (P¼0.065).
Discussion
We detected a steady decline in the frequency of erythromycin resistance from 2005 onward among S. pyogenes isolates circulating in Gipuzkoa, northern Spain. These results contrast with those observed in recent decades, where erythromycin resistance was ascending or remained stable and close to 20% -25% until 2004. 2 -5 The 2.8% erythromycin resistance rate recorded in 2012 was the lowest rate in our region since 1999. Similar decreasing trends have also been documented in other regions of Spain 7, 18 and in neighbouring countries such as Portugal, where the erythromycin resistance rate dropped from 20% -23% in 1999 -2003 to 10% in 2007, 19 or France, where it declined from 24% in 2002-03 to 3.2% in 2009 -11 among children with pharyngitis. 20 In the present study, the M phenotype was the predominant resistance phenotype except for in 2005, when two of the three main circulating erythromycin-resistant clones (emm11/ST403 and emm28/ST52) harboured an erm(B) gene. In Spain, until 2004, the M phenotype was also the predominant phenotype among macrolide-resistant S. pyogenes isolates. 4, 5 High antibiotic consumption has been directly associated with an increase of antibiotic resistance in Spain and elsewhere, because it positively selects erythromycin-resistant isolates; 21, 22 however, macrolide consumption remained relatively stable during the present study. Four clones (emm12/ST36, emm11/ ST403/ST20/ST21, emm28/ST52 and emm4/ST39) accounted for almost 90% of all resistant isolates. These emm types (or emm types/STs when STs were determined) are frequently detected in different regions among erythromycin-resistant isolates. 2,18,23 -25 The turnovers of these predominant resistant clones seem to have been the major factor influencing the decrease in resistance. The progressive decrease of multiresistant emm11/ST403/ST20/ST21 and emm28/ST52 clones expressing the MLS B phenotype was accompanied by an initial increase of emm12/ST36 isolates carrying the mef(A) gene, which overall comprised the predominant resistant clone in the present study. In 2006, the peak in erythromycin resistance coincided with the dissemination of the emm4/ ST39 clone harbouring the mef(A) gene, once again reinforcing the clear influence of clone circulation on the prevalence of resistance. Both the emm4/ST39 and emm12/ST36 clones are widely disseminated throughout the five continents. 25 This success may be associated with a lower biological cost (fitness cost) of isolates with an efflux pump mediated by mef(A) genes compared with alterations in ribosomal targets.
The antibiotics frequently associated with erythromycin resistance, such as clindamycin, tetracycline and bacitracin, also showed a decreasing resistance trend throughout the study period.
Fortunately, high-level fluoroquinolone resistance was rare in our region 26 and elsewhere. 6, 17 Low-level fluoroquinolone resistance increased over the last 3 years of the study, from 3% in 2010 to 13.9% in 2012, being mainly due to the circulation of emm6/ST382 isolates, the principal clone associated with this resistance. 17, 26 From 2005 to 2012, the emm6/ST382 isolates were mostly susceptible to macrolides.
Coresistance to erythromycin and fluoroquinolones was low, not exceeding 0.3% of total isolates and coresistance to erythromycin and tetracycline was found in 1.7%. The main cause of erythromycin and tetracycline coresistance was the emm11/ ST403 clone, which was very prevalent in our region in previous years and carried the erm(B), tet(M), intTn and xis genes. 4 As expected, the predominant forms of macrolide resistance in S. pyogenes were mediated by mef(A) genes encoding an efflux pump or by erm-family genes encoding ribosomal methylases. 27 A high correspondence was observed between macrolide gene content and the expressed phenotype. Nevertheless, in two emm75/ST150 isolates expressing the MLS B phenotype, the mechanism responsible for erythromycin resistance was a mutation (A2058G) in domain V of the 23S gene. This mutation is very unusual, but has previously been reported to be a cause of erythromycin resistance in S. pyogenes 16 and in S. pneumoniae, 28 conferring resistance to macrolides, streptogramin B and clindamycin. Only 3.2% of erythromycin-resistant isolates carried more than one resistance gene, indicating possible independent erythromycin-resistance determinant acquisitions by major resistant clones, but without success in their dissemination. In a bivariate analysis, pharyngeal isolates showed less erythromycin resistance than skin isolates (P ¼ 0.007), but more resistance than ear isolates (P, 0.001). Nevertheless, when age of patients and anatomical origin of isolates were considered in a logistic regression analysis, only ear isolates showed significantly lower resistance independent of the patient age. Among skin isolates, perianal isolates frequently belonged to the emm28/ST52 clone. Most erythromycin-resistant emm28/ST52 isolates were Figure 2 . Erythromycin, clindamycin, tetracycline and bacitracin resistance rates among S. pyogenes isolates obtained from children (n ¼9784) and adult (n ¼2378) patients.
bacitracin resistant and seemed to have a special tropism for genital and perianal regions. In other studies, emm28 isolates have often been recovered from puerperal sepsis and perianal or gynaecological infections. 29, 30 These isolates have acquired a region encoding adhesins conferring a preference site for infection, the genital trait; 30 therefore, we believe that bacitracin resistance could have been acquired by S. pyogenes isolates from other bacitracin-resistant streptococci of genital or intestinal origin.
No emm type was fully linked to erythromycin resistance. The emm types containing the highest proportion of erythromycinresistant isolates were emm11, emm12 and emm28. Other studies from southern Europe have also found associations of these emm types with erythromycin resistance. 20, 31, 32 The resistance among isolates belonging to a particular emm type depends on the genetic composition of these isolates (different clones or subclones within an emm type) and on how each of them circulates in a specific region in a given period. In Portugal, Silva-Costa et al. found some subclones within the emm12 or emm28 isolates showing mostly erythromycin resistance while other subclones of the same emm type were fully susceptible. 31 Type emm4 was very prevalent in our region and most isolates were erythromycin susceptible. Nevertheless, a minority of emm4 subclones contributed substantially to erythromycin resistance in our region. Isolates characterized as emm12 and emm4 caused 53.7% of total resistance and 85.6% of the M resistance phenotype. Isolates characterized as emm2 and emm87 were exclusively found among erythromycin-susceptible isolates. Otherwise, emm1, emm58, emm77 and emm89 were found only among erythromycin-susceptible isolates in the random selection, but were present as minor erythromycin-resistant clones.
Although the present study was conducted in a limited geographic area, it included all S. pyogenes isolates detected in the routine clinical care of patients of all ages with diverse clinical presentations over a long period with an extensive characterization. The steady decline in the frequency of erythromycin resistance was remarkable. This resistance decreased without appreciable changes in drug consumption; hence, we think that acquired immunity to the four major resistant clones may have been the main driver of this decline.
